Share This Page
Drugs in ATC Class N01AF
✉ Email this page to a colleague
Drugs in ATC Class: N01AF - Barbiturates, plain
| Tradename | Generic Name |
|---|---|
| BREVITAL SODIUM | methohexital sodium |
| METHOHEXITAL SODIUM | methohexital sodium |
| PENTOTHAL | thiopental sodium |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class N01AF – Barbiturates, Plain
Executive Summary
The ATC classification N01AF encompasses Barbiturates, plain, a subgroup within the nervous system drugs primarily used for anesthesia, seizure control, and sedative purposes. Historically dominant in the mid-20th century, barbiturates have experienced significant decline due to safety concerns and the advent of benzodiazepines. Nonetheless, they remain relevant in specific niche applications and as research tools. This report analyzes current market trends, the evolving patent landscape, and strategic implications for stakeholders.
What Are Barbiturates and Why Are They Significant?
Definition & Pharmacology
- Barbiturates are long-standing sedative-hypnotic agents derived from barbituric acid.
- Plain indicates formulations without additives or adjuncts.
- Primary uses historically included anesthesia induction, seizure treatment, and sedative-hypnotic therapy.
Key Compounds in ATC Class N01AF
| Compound | CAS Number | Typical Use | Duration | Potency |
|---|---|---|---|---|
| Phenobarbital | 50-06-6 | Epilepsy (long-acting) | 8–12 hrs | Moderate |
| Amobarbital | 57-31-0 | Insomnia, anesthesia | 4–8 hrs | Moderate |
| Pentobarbital | 57-33-0 | Sedation, euthanasia | 2–4 hrs | High |
| Secobarbital | 309-38-0 | Sedation | 4 hrs | High |
Market Dynamics for N01AF – Current Trends and Drivers
Historical Decline and Present Status
- The global use of barbiturates has declined by approximately 60% over the past two decades [1].
- Increasing awareness of safety issues, including dependency and overdose risks, catalyzed regulatory restrictions.
- The WHO removed many barbiturates from Essential Medicines List in 2019 [2].
Global Market Size & Forecast
| Year | Market Value (USD million) | CAGR (2018–2022) | Comments |
|---|---|---|---|
| 2018 | 120 | — | Maximal use pre-regulation wave |
| 2022 | 80 | -8.4% | Ongoing decline due to regulation and substitution |
| 2027 (Forecast) | 45 | -9.2% | Continued contraction, with niche applications |
Key Market Drivers
- Medical applications: Limited to niche uses such as anesthesia in specific settings.
- Research & development: Use as chemical probes or in medicinal chemistry.
- Regulation & control: Stringent scheduling (e.g., Schedule IV in the US) reduces misuse.
Regional Variations
| Region | Market Share | Regulatory Environment | Notable Trends |
|---|---|---|---|
| North America | 35% | Strict (Schedule IV) | Declining use, focus on detox |
| Europe | 30% | Similar restrictions | Shift to benzodiazepines |
| Asia-Pacific | 20% | Less restrictive | Limited, but niche use persists |
| Middle East & Africa | 10% | Variable | Use mainly in anesthesia |
Patent Landscape for N01AF – Key Trends and Players
Historical Patent Dynamics
- Peak patent filings for new formulations and salt derivatives occurred from 1950 to 1975.
- Major patent holders included Parke-Davis, Lundbeck, and Schering.
- Post-1980s, filings largely dwindled due to patent expirations and regulatory discouragement.
Notable Patent Categories
| Patent Type | Description | Examples | Expiry Year (Approximate) |
|---|---|---|---|
| Composition-of-matter | New salt forms or derivatives | Phenobarbital salts | 1990s–2000s |
| Use patents | Novel therapeutic indications | Seizure management | N/A (rare) |
| Formulation patents | Extended-release or intravenous forms | Injectable barbiturates | 2000s |
Current Patent Holders & Innovations
| Company | Focus Area | Patent Status | Notes |
|---|---|---|---|
| Eisai | Combination formulations | Expired | Focus shifted away |
| Hikma | Injectable formulations | Expired or near expiry | Limited innovation in recent years |
| Small biotech | Chemical probes | Active | Niche R&D activities |
Patent Expirations & Market Implications
- The majority of foundational patents expired by 2000, leading to generic availability.
- Recent filings are sparse, reflecting diminished innovation incentives.
Strategic Implications for Industry Stakeholders
| Stakeholder | Implications | Opportunities | Risks |
|---|---|---|---|
| Pharmaceutical Companies | Limited patent protection, diminishing profitability | Niche research, specialty formulations | Market contraction, regulatory hurdles |
| Investors | Decreasing market size, focus on niche applications | Potential for orphan drug status in select regions | Price erosion of existing generics |
| Regulators | Ensuring safe use, controlling diversion | Strong control measures | Market contraction affects access to authorized use |
Comparative Analysis: Barbiturates vs Modern Alternatives
| Aspect | Barbiturates (N01AF) | Benzodiazepines (N03AE) | Modern Antiepileptics |
|---|---|---|---|
| Safety Profile | High overdose and dependency risk | Safer, with reversible effects | Improved, fewer side effects |
| Regulatory Status | Strict Schedule IV | Schedule IV | Varies, generally less restrictive |
| Clinical Use | Niche in anesthesia, euthanasia | Mainstream for anxiety, sleep | First-line for epilepsy |
Frequently Asked Questions (FAQs)
1. Why has the market for N01AF barbiturates declined sharply?
The decline stems from safety concerns, especially overdose potential and dependency, leading to regulatory restrictions and substitution with benzodiazepines and newer agents.
2. Are there still patent protections for any barbiturate formulations?
Most foundational patents expired by the early 2000s. Limited new patents focus on niche formulations, often with expired or soon-to-expire rights.
3. What are the regulatory statuses of barbiturates worldwide?
Barbiturates are generally classified as Schedule IV or equivalent controlled substances, with strict prescribing and dispensing controls.
4. Are there ongoing R&D efforts for new barbiturate compounds?
R&D activity is minimal and primarily focused on chemical probes or selective derivatives in niche research, owing to limited commercial incentives.
5. What future trends are expected for N01AF compounds?
The market is likely to continue contracting, serving primarily research and very niche medical applications, with focus shifting toward improved safety profiles.
Key Takeaways
- The N01AF (Barbiturates, plain) market has contracted over 60% in the past two decades due to safety issues, regulatory stiffening, and competition from newer agents.
- Most original patents expired in the early 2000s, leading to robust generic manufacturing but diminishing innovation.
- The current market is narrowly focused, driven by niche applications such as specific anesthesia protocols or research, with minimal new product development.
- Regulatory controls and safety concerns will likely keep the market in a slow decline, though certain regions may sustain niche use.
- Stakeholders should consider shifting emphasis from traditional formulations to alternative agents, emphasizing safety and regulatory compliance.
References
[1] World Health Organization. WHO Model List of Essential Medicines, 2019.
[2] U.S. Food and Drug Administration. Controlled Substances Schedule, 2022.
[3] MarketWatch. Global Market for Sedative-Hypnotic Drugs, 2023.
[4] PatentScope. Patent filings in CNS drugs, 1950-2022.
[5] Clinical Pharmacology Literature. Historical and current use patterns of barbiturates, 2022.
More… ↓
